

PROGRAM OVERVIEW

A. Mission

The *Early Career Investigator Award in Pulmonary Vascular Disease* is a program designed for basic science, translational and clinical research in the field of Pulmonary Vascular Disease. The Program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, translational and clinical research) in the area of pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular pathobiology and ultimately, to improve treatment for patients with pulmonary hypertension.

B. Description

The name of the program was originally established as ENTELLIGENCE by Actelion Pharmaceuticals US, Inc. in 2005. The program provides individual grants of up to \$100,000 to qualified investigators to conduct research via a 12-month mentored grant. These grants are awarded by the Program Steering Committee to qualified investigators who show promise in their investigations and are based on scientific merit, originality, feasibility, and applicability to the diagnosis and treatment of PH. A condition of the grant application and funding is supervision by an appropriate mentor. Applications will be considered for basic science, translation or clinical research specifically targeting pulmonary vascular disease including, but not limited to, the following areas:

- Pathophysiology
- Pharmacology
- Treatment
- Genetics
- Diagnosis
- Epidemiology

Receipt of a grant in no way requires the recipient, nor implies that the recipient is obligated to, recommend or prescribe any products. The main focus of the project should be to develop a better understanding of an approach to disorders of pulmonary vascular biology, particularly PH. Bridge funding, therapeutic drug trials (eg. efficacy and safety evaluation), and registries are not eligible. The projects must be achievable within the time frame (1 year) and budget allocation of up to \$100,000. Additional funding sources are acceptable and must be clearly identified.

C. Steering Committee

Since the inception of the program Steering Committee members have selected and approved all new and replacement members. The Steering Committee membership selection process ensures a wide variety of expertise, experience, and opinion as well as a geographic representation throughout the United States and Canada. The Steering Committee consists of 9 members.

The duties and obligations of the Steering Committee Chairperson include corresponding with ATS regarding document finalization, supervising the grant process, and supporting public awareness of the Program. The Steering Committee members of the program have the following duties and obligations:

1. Review and rank grant applications and decide on the final distribution and size of grants to the applicants
2. Ensure a fair and timely grant application review, approval, and award procedure
3. Guide strategic decisions and contributions to the improvement of the Program
4. Participate in meetings and conference calls, as required, in support of the Program

D. Submission Process

A full grant submission is submitted with all necessary documents. If your proposal is approved for funding, you and your mentor will be responsible for all aspects of your research. You will be provided with a grant application agreement, which you must sign and return within 90 days of notification of the award, along with the requested documents.

Disclosure: This ATS Early Career Investigator Award in Pulmonary Vascular Disease was formerly known as ENTELLIGENCE